Stockscreener 앱 받기
54.86
1.29%
0.70
시간 외 거래:
54.90
0.04
+0.07%
전일 마감가:
$54.16
열려 있는:
$54.29
하루 거래량:
2.05M
Relative Volume:
0.98
시가총액:
$10.53B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
20.39
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+2.03%
1개월 성능:
-5.85%
6개월 성능:
-19.25%
1년 성능:
-21.74%
1일 변동 폭
$54.26
$55.75
1주일 범위
$52.48
$55.75
52주 변동 폭
$52.48
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.86 | 10.40B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
404.21 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.94 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.65 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
767.33 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.16 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
Take Care Before Diving Into The Deep End On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth - GlobeNewswire Inc.
How institutional ownership impacts BioMarin Pharmaceutical Inc. stockEarnings Risk Summary & Real-Time Volume Analysis Alerts - newser.com
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks - Seeking Alpha
Tealwood Asset Management Inc. Increases Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT - Yahoo
Real time alert setup for BioMarin Pharmaceutical Inc. performanceCPI Data & Fast Moving Trade Plans - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetEarnings Trend Report & Precise Trade Entry Recommendations - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationRate Cut & Daily Profit Maximizing Trade Tips - newser.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring a Compelling 78% Upside Potential - DirectorsTalk Interviews
Is BioMarin Pharmaceutical Inc a good long term investmentRetail Investor Activity & Optimize Entry & Exit With Smart Signals - earlytimes.in
What analysts say about BioMarin Pharmaceutical Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Is BioMarin Pharmaceutical Inc BM8 a good long term investmentPrice Volatility Patterns & Superior Wealth Growth - earlytimes.in
BioMarin Pharmaceutical Hits New 52-Week Low at $52.48 - Markets Mojo
Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Wealth Enhancement Advisory Services LLC Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at $52.93 By Investing.com - Investing.com Nigeria
Perpetual Ltd Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at $52.93 - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 12-Month LowTime to Sell? - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Covea Finance - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update - MarketBeat
Strs Ohio Buys Shares of 16,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.(NasdaqGS: BMRN) dropped from FTSE All-World Index - MarketScreener
Assenagon Asset Management S.A. Purchases 230,362 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Acadian Asset Management LLC Reduces Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aug Movers: Why is BioMarin Pharmaceutical Inc. stock going upOil Prices & Community Trade Idea Sharing - خودرو بانک
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Intech Investment Management LLC - MarketBeat
Performance Recap: Should I invest in BioMarin Pharmaceutical Inc before earningsJuly 2025 Decliners & Expert Verified Movement Alerts - خودرو بانک
Wesbanco Bank Inc. Purchases 19,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - sharewise.com
Aug PreEarnings: What is the target price for BioMarin Pharmaceutical Inc stockBond Market & Fast Gain Stock Trading Tips - خودرو بانک
Aug Action: Is BioMarin Pharmaceutical Inc. stock forming a cup and handleWeekly Trend Summary & Stepwise Swing Trade Plans - khodrobank.com
12 Best Beginner Stocks to Buy According to Analysts - Insider Monkey
Ideas Watch: How does BioMarin Pharmaceutical Inc score in quality rankingsEarnings Performance Report & Real-Time Buy Signal Notifications - خودرو بانک
Levels Update: Can BioMarin Pharmaceutical Inc. scale operations efficientlyQuarterly Trade Summary & Consistent Growth Equity Picks - khodrobank.com
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - Insider Monkey
November 21st Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 - MSN
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Goldman Sachs Group Inc. - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $75.28 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) - MSN
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.95%
1.63%
자본화:
|
볼륨(24시간):